Celltaxis Promotes Eileen Heffernan to CEO

Celltaxis, a clinical-stage biotechnology company dedicated to developing novel therapies for lymphatic diseases, has promoted Eileen Heffernan to Chief Executive Officer (CEO). Heffernan is a co-founder of Celltaxis and previously served as Chief Business Officer. 

“Eileen has been a driving force behind Celltaxis since its founding and has played a critical role in shaping the Company, from corporate strategy and business development to financing and clinical advancement,” said Eric Springman, Ph.D., Co-Founder and Chief Scientific Officer of Celltaxis. “I look forward to continuing our work to establish Celltaxis as a leading company focused on developing much-needed therapies for lymphatic diseases.” 

Experience 

Heffernan brings more than 30 years of biopharmaceutical industry experience spanning corporate strategy, business development, licensing, and mergers and acquisitions. She has helped advance more than 20 regulated medical technologies and therapeutic programs and has led strategic transactions with leading healthcare organizations including SmithKline, Sanofi, Merck, and Pasteur Merieux. 

“The field of lymphatic medicine is approaching an important inflection point,” said Heffernan. “I look forward to working alongside our talented team, advisors and partners to advance our clinical programs, expand strategic collaborations, and establish Celltaxis as a leader in lymphatic disease therapeutics.”